IntegReview
IntegReview, operating as Advarra, is the largest central Institutional Review Board providing ethical oversight for industry-sponsored clinical trials, serving pharma, biotechs, CROs, and 72,000+ research sites across the U.S. and Canada via its proprietary CIRBI platform and Braid AI engine.
- Company typePrivate
- Founded1977
- HeadquartersAustin, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What IntegReview does
IntegReview operates today as Advarra, the largest central Institutional Review Board (IRB) in the independent segment, providing ethical oversight and protocol review for the majority of industry-sponsored clinical trials in the United States and Canada. The company was formed in 1977 through the unification of several leading independent IRBs — IntegReview among them — combining their governance models and reviewer expertise into a single platform. Advarra supports more than 72,000 research sites and reviews 36,000+ U.S. site submissions and 1,600+ Canadian submissions annually, with deep specialization in oncology (2x more oncology protocols reviewed than any other independent IRB, 100% of oncology indications, 7x more oncology-representative meetings per week, and 400+ oncology experts on roster).
The product surface centers on the proprietary CIRBI platform — a secure, single-source-of-truth system for IRB submissions, required actions, study status, and board decisions — integrated with sponsor-side Study Collaboration tooling, the Braid Data and AI Engine (powering the 2024 Study Design Solution), and a portfolio of site-side systems (OnCore and Clinical Conductor CTMS, eReg, eSource). Adjacent review services include Institutional Biosafety Committee (IBC), Data Monitoring Committee (DMC), and GxP compliance offerings. Preferred-provider relationships cover all NCI Designated Cancer Centers plus SCRI and START.
Revenue is generated through quote-based, subscription-style contracts for IRB and ancillary review services, sold primarily via an enterprise direct-sales motion (dedicated coordinators serve as single points of contact) supplemented by the CIRBI portal for ongoing submission management. The customer base spans emerging biotechs, all top-20 pharmaceutical companies, leading CROs, and 72,000+ research sites, with 87% of submissions coming from returning customers — evidence of a durable, recurring revenue model anchored in regulatory necessity rather than discretionary spend.
IntegReview firmographics
Firmographics- Name
- IntegReview
- Legal name
- Advarra
- Website
- https://integreview.com
- Company type
- Private
- Founded year
- 1977
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- IntegReview, operating as Advarra, is the largest central Institutional Review Board providing ethical oversight for industry-sponsored clinical trials, serving pharma, biotechs, CROs, and 72,000+ research sites across the U.S. and Canada via its proprietary CIRBI platform and Braid AI engine.
- Ownership category
- akta.pro rank
IntegReview industry classification
Industry- Product category
- Clinical Research Ethics Review Services
- NAICS
- Other Scientific and Technical Consulting Services (54169)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Clinical Research Ethics & Human Subjects Protection Authorities (IRB/REC Oversight) (HLAJACAG)
- akta.pro secondary industries
- Clinical CROs (Phase I–IV) (HLAGAAAA), Clinical Research Support (CRC/CTA) (EDAOAJAO)
Keywords
Where IntegReview is headquartered
LocationHeadquarters
- HQ city
- Austin
- HQ country
- United States
- HQ region
- North America
Markets served
IntegReview business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Others
Revenue model
- IRB Review Services: Advarra provides ethical oversight and review services for clinical trials. They are described as the largest central IRB providing independent, rigorous oversight for the majority of industry-sponsored trials.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Custom enterprise pricing based on organization needs and submission volume |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
IntegReview product offering
Product offeringCore offering
IntegReview provides independent Institutional Review Board (IRB) services for industry-sponsored clinical trials, delivering ethical oversight, protocol review, and ongoing study review across the United States and Canada. The offering is delivered through the CIRBI proprietary platform and is supported by adjacent review services including Institutional Biosafety Committee (IBC), Data Monitoring Committee (DMC), and GxP compliance intelligence, primarily to pharmaceutical and biotech sponsors, CROs, and more than 72,000 research sites.
Product overview
Advarra offers a unified IRB platform combined with clinical trial technology solutions. The core offering is CIRBI, a proprietary IRB platform that serves as the single source of truth for submissions, required actions, study status, and board decisions. This integrates with the Study Collaboration platform for sponsors and CROs, and CTMS solutions (OnCore, Clinical Conductor) for sites. The Braid Data and AI Engine powers study design and operational automation. Additional offerings include IBC Services, DMC Services, GxP Compliance Intelligence, eReg, and eSource for regulatory and clinical documentation management.
Differentiator
Problem solved
Functional benefit
Brands
- CIRBI: Advarra's secure, proprietary platform that supports the gold-standard IRB process. A single source of truth for submissions, required actions, study status, and board decisions.
Products and services
- IRB Services Independent, rigorous Institutional Review Board oversight with speed and transparency, providing ethical oversight for industry-sponsored trials across more than 72,000 research sites serving emerging biotechs through top-20 pharma and leading CROs.
- IBC Services Institutional Biosafety Committee services reviewing the biosafety aspects of research, particularly for advanced therapeutic modalities such as cell and gene therapy.
- DMC Services Data Monitoring Committee services providing oversight of safety data in clinical trials.
- GxP Compliance Intelligence GxP compliance intelligence services providing reviews and audits to support regulatory compliance in clinical research.
- OnCore CTMS Clinical Trial Management System solution used by research sites and institutions to manage clinical trial operations.
- Clinical Conductor CTMS Clinical Trial Management System solution used by research sites and institutions to manage clinical trial operations.
- eReg Electronic regulatory management solution for sites and institutions, with direct integration to IRB submissions to streamline documentation.
- eSource Electronic source documentation solution for sites and institutions to capture clinical trial source data electronically.
- Study Collaboration Platform for sponsors and CROs to collaborate on study design, site identification and feasibility, study startup, site collaboration and training, and enrollment planning and tracking.
- Braid Data and AI Engine Data and AI engine powering study design and other operational intelligence and automation solutions for clinical trials.
Quantifiable outcome
- First decisions on protocol submissions average five days after all required materials are received
- +3 more outcomes
Companies that use IntegReview
Customer profileNamed customers6 records
Segments4 records
Ideal customer profiles3 records
IntegReview technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
Feature2 records
IntegReview partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- SCRI (Sarah Cannon Research Institute)coreAdvarra is the preferred provider for IRB and IBC services for SCRI's late-stage trials. This partnership leverages SCRI's oncology research expertise with Advarra's regulatory oversight capabilities.
- START (South Texas Accelerated Research Therapeutics)coreAdvarra and START united to deliver unmatched speed, quality, and predictability for early-phase oncology trials. Advarra serves as preferred IRB and IBC partner for START's early-phase oncology research.
- NCI Designated Cancer CenterscoreAdvarra supports all NCI Designated Cancer Centers with IRB services, providing ethical oversight for oncology research conducted across these prestigious research institutions.
Scale indicators11 records
Recent moves6 records
Expansion highlights5 records
IntegReview competitors and assessment
Company assessmentMarket position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
IntegReview social profiles
Digital presenceIntegReview financial estimates
Financial estimateRevenue estimate
Valuation estimate
IntegReview leadership team
Management profileNumber of profiles
Profiles1 record
IntegReview funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
IntegReview M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about IntegReview
What does IntegReview do?
IntegReview provides independent Institutional Review Board (IRB) services for industry-sponsored clinical trials, delivering ethical oversight, protocol review, and ongoing study review across the United States and Canada. The offering is delivered through the CIRBI proprietary platform and is supported by adjacent review services including Institutional Biosafety Committee (IBC), Data Monitoring Committee (DMC), and GxP compliance intelligence, primarily to pharmaceutical and biotech sponsors, CROs, and more than 72,000 research sites.
Is IntegReview a public or private company?
IntegReview is a private company. It is classified as unknown and is currently operating.
When was IntegReview founded?
IntegReview was founded in 1977. It employs 11 to 50 people.
Where is IntegReview based?
IntegReview is headquartered in Austin, United States, in the North America region.
How does IntegReview make money?
One revenue line is on record: IRB Review Services.
Does IntegReview have an API?
No public API is recorded for IntegReview.
What industry is IntegReview in?
IntegReview's product category is Clinical Research Ethics Review Services. Its primary akta.pro industry code is HLAJACAG, Clinical Research Ethics & Human Subjects Protection Authorities (IRB/REC Oversight), with a secondary code of HLAGAAAA, Clinical CROs (Phase I–IV). Its NAICS code is 54169 and its SIC code is 8731.